06:44 AM EST, 12/20/2024 (MT Newswires) -- Hims & Hers Health ( HIMS ) shares were down more than 3.5% in Friday's premarket activity after closing down 7.7% on Thursday following a US Food and Drug Administration determination that a shortage of Eli Lilly's ( LLY ) popular weight loss drug tirzepatide has ended.

Hims & Hers Health ( HIMS ) was allowed to produce its version of the drug as long as the FDA determined there was a shortage.

The FDA said in a letter on Thursday that "the tirzepatide injection product shortage is resolved."